Guggenheim resumed coverage on Five Prime Therapeutics with a new price target
$FPRX
Major Pharmaceuticals
Health Care
Guggenheim resumed coverage of Five Prime Therapeutics with a rating of Neutral and set a new price target of $38.00
Save time and jump to the most important pieces.